Skip to content

Clinical trials

Recruiting Neuromuscular Diseases trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neuromuscular Diseases Phase: Not applicable Status: Recruiting Clear all

22 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20131
20141
20191
20222
20233
20246
20252
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting22

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2
ABLE Human Motion S.L.1
Assistance Publique - Hôpitaux de Paris1
Centre Hospitalier Universitaire de Liege1
Cliniques universitaires Saint-Luc- Université Catholique de Louvain1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1
Groupe Hospitalier du Havre1
Guy's and St Thomas' NHS Foundation Trust1
Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato1
Laurent Servais1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neuromuscular Diseases22
Amyotrophic Lateral Sclerosis4
Myotonic Dystrophy4
Charcot-Marie-Tooth Disease3
Muscular Dystrophy, Facioscapulohumeral3
Cerebral Palsy2
Lambert-Eaton Myasthenic Syndrome2
Motor Neuron Disease2
Myasthenia Gravis2
Myotonia Congenita2

Trials

Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.